Insider · CIK 0001638474

Albers Jeffrey W.

Reports to the SEC for 4 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001638474

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-07	SYRESpyre Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$10.39	+$52K	5,000
2026-08-07	SYRESpyre Therapeutics, Inc.S Sale	Director	SSale	−8,000 sh	$104.38	−$835K	19,360
2026-08-07	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	45,000
2026-08-07	SYRESpyre Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$104.68	−$1.05M	9,360
2026-08-07	SYRESpyre Therapeutics, Inc.S Sale	Director	SSale	−5,000 sh	$104.47	−$522K	0
2026-06-24	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,068 sh	—	—	6,068
2026-05-27	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,026 sh	—	—	8,026
2025-12-08	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−2,252 sh	$90.30	−$203K	0
2025-12-08	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−2,748 sh	$89.32	−$245K	2,252
2025-12-08	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	7,000
2025-12-08	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$14.18	+$70.9K	5,000
2025-10-13	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−5,000 sh	$59.19	−$296K	0
2025-10-13	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$10.34	+$51.7K	5,000
2025-10-13	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	0
2025-07-17	Blueprint Medicines CorpD Disposition to Issuer	Director	DDisposition to Issuer	−5,777 sh	—	—	144,755
2025-07-17	Blueprint Medicines CorpU Disposition from Tender	Director	UDisposition from Tender	−145K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−4,570 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−92.5K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−170K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−111K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,300 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−80K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−90K sh	—	—	0
2025-06-25	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2025-06-18	Blueprint Medicines CorpA Award	Director	AAward	+3,902 sh	$128.12	+$500K	150,532
2025-06-03	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,349 sh	—	—	5,000
2025-06-03	KYMRKymera Therapeutics, Inc.S Sale	Director	SSale	−6,349 sh	$49.00	−$311K	0
2025-06-03	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+6,349 sh	$10.34	+$65.6K	6,349
2025-05-29	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2025-05-27	Blueprint Medicines CorpS Sale	Director	SSale	−4,350 sh	$101.02	−$439K	147,280
2025-05-27	Blueprint Medicines CorpS Sale	Director	SSale	−650 sh	$101.93	−$66.3K	146,630
2025-05-27	Blueprint Medicines CorpM Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$36.05	+$180K	151,630
2025-05-27	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	92,500
2025-03-12	Blueprint Medicines CorpS Sale	Director	SSale	−1,800 sh	$88.37	−$159K	152,396
2025-03-12	Blueprint Medicines CorpS Sale	Director	SSale	−5,700 sh	$87.62	−$499K	154,196
2025-03-12	Blueprint Medicines CorpM Exercise/Conversion	Director	MExercise/Conversion	+7,500 sh	$36.05	+$270K	159,896
2025-03-12	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−7,500 sh	—	—	97,500
2025-03-05	Blueprint Medicines CorpS Sale	Director	SSale	−5,766 sh	$88.80	−$512K	146,630
2025-01-21	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	105,000
2025-01-21	Blueprint Medicines CorpM Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$36.05	+$361K	167,557
2025-01-21	Blueprint Medicines CorpS Sale	Director	SSale	−7,561 sh	$109.11	−$825K	159,996
2025-01-21	Blueprint Medicines CorpS Sale	Director	SSale	−7,400 sh	$109.92	−$813K	152,596
2025-01-21	Blueprint Medicines CorpS Sale	Director	SSale	−200 sh	$110.61	−$22.1K	152,396
2025-01-13	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	115,000
2025-01-13	Blueprint Medicines CorpS Sale	Director	SSale	−5,000 sh	$102.28	−$511K	157,557
2025-01-13	Blueprint Medicines CorpM Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$36.05	+$180K	162,557
2024-12-19	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−15K sh	$36.05	−$541K	120,000
2024-12-19	Blueprint Medicines CorpS Sale	Director	SSale	−2,100 sh	$91.96	−$193K	157,557
2024-12-19	Blueprint Medicines CorpS Sale	Director	SSale	−3,800 sh	$91.15	−$346K	159,657

Recent filings

Accepted (ET)
Aug 104
Albers Jeffrey W.0001636282-26-000102
SEC(opens sec.gov)
Jun 254
Albers Jeffrey W.0001193125-26-283136
SEC(opens sec.gov)
May 294
Albers Jeffrey W.0001636282-26-000068
SEC(opens sec.gov)
Dec 84
Albers Jeffrey W.0001193125-25-311505
SEC(opens sec.gov)
Oct 144
Albers Jeffrey W.0001193125-25-238130
SEC(opens sec.gov)
Jul 214
Albers Jeffrey W.0001104659-25-069377
SEC(opens sec.gov)

Companies

Address

221 CRESCENT STREET, BUILDING 23, SUITE 105

WALTHAM, MA, 02453